Retatrutide vs Semaglutide: Differences in Evidence, Status and Regulation
Retatrutide and Semaglutide are compared below on structure, research stage, registered clinical studies, and regulatory status, using the same sourced data shown on each entry page. This comparison is descriptive and does not rank either peptide.
Comparison table
| Dimension | Retatrutide | Semaglutide |
|---|---|---|
| Category | GLP-1 / incretin | GLP-1 / incretin |
| Research status | Investigational | Approved drug |
| Origin | No data | No data |
| Amino acids | No data | No data |
| Molecular weight | No data | No data |
| Overall evidence level | No data | No data |
| Human evidence rows in our table | No data | No data |
| Registered studies (ClinicalTrials.gov) | 34 | 710 |
| Most advanced registered phase | Phase 3 | Phase 4 |
| Half-life (sourced) | No data | No data |
| Status: United States | No data | No data |
| Status: European Union | No data | No data |
| Status: United Kingdom | No data | No data |
| Status: WADA (sport) | No data | No data |
Key differences
- Research status differs: Retatrutide is listed as "Investigational" and Semaglutide as "Approved drug".
- ClinicalTrials.gov lists 34 registered studies matching Retatrutide and 710 matching Semaglutide.
- The most advanced registered phase is Phase 3 for Retatrutide and Phase 4 for Semaglutide.
Entry pages
Full sources, evidence tables, and regulatory details are on each entry page: Retatrutide and Semaglutide.
This comparison does not rank the two peptides and does not suggest that either one is appropriate for any use.